- 专利标题: NOVEL FGFR3 FUSION PRODUCT
-
申请号: EP13757006.5申请日: 2013-03-07
-
公开(公告)号: EP2824181B1公开(公告)日: 2018-11-14
- 发明人: SUZUKI, Atsushi , ASAUMI, Makoto , TSUNOYAMA, Kazuhisa , NISHIMURA, Kouichi , MORINAKA, Akifumi , YAMAUCHI, Tomohiro , YOSHINO, Masayasu , YOSHIZAKI, Hiroaki
- 申请人: Astellas Pharma Inc.
- 申请人地址: 5-1, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 JP
- 专利权人: Astellas Pharma Inc.
- 当前专利权人: Astellas Pharma Inc.
- 当前专利权人地址: 5-1, Nihonbashi-Honcho 2-chome Chuo-ku Tokyo 103-8411 JP
- 代理机构: Hoffmann Eitle
- 优先权: JP2012052147 20120308; JP2012195451 20120905; JP2012280325 20121221
- 国际公布: WO2013133351 20130912
- 主分类号: C12Q1/6886
- IPC分类号: C12Q1/6886
摘要:
[Problem] The present invention aims to elucidate a polynucleotide as a novel responsible gene for cancer and aims to thus provide a method for detecting the polynucleotide and a polypeptide encoded by the polynucleotide and a detection kit, a probe set, and a primer set for the detection. The present invention also aims to provide a pharmaceutical composition for treating cancer. [Means for Solution] The method detects a fusion gene composed of a portion of an FGFR3 gene and a portion of a TACC3 gene or a fusion protein encoded by the fusion gene. The primer set, the probe set, or the detection kit comprises a sense primer and a probe set designed from the portion encoding FGFR3 and an antisense primer and a probe set designed from the portion encoding TACC3. Since an inhibitor of the polypeptide exhibits antitumor effect, a pharmaceutical composition for treating cancer which is positive for either the fusion gene or the polypeptide is provided.
公开/授权文献
- EP2824181A1 NOVEL FGFR3 FUSION PRODUCT 公开/授权日:2015-01-14
信息查询
IPC分类: